StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Free Report) in a research report report published on Tuesday. The brokerage issued a sell rating on the basic materials company’s stock.
Other equities research analysts also recently issued reports about the company. Lake Street Capital upgraded Arcadia Biosciences to a strong-buy rating in a report on Tuesday, May 14th. HC Wainwright reduced their price target on Arcadia Biosciences from $10.00 to $6.00 and set a buy rating for the company in a research report on Thursday, May 23rd.
Get Our Latest Stock Analysis on Arcadia Biosciences
Arcadia Biosciences Stock Down 2.9 %
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The basic materials company reported ($1.78) EPS for the quarter, beating the consensus estimate of ($2.52) by $0.74. The company had revenue of $1.26 million during the quarter, compared to analysts’ expectations of $1.20 million. Arcadia Biosciences had a negative return on equity of 84.27% and a negative net margin of 129.74%. During the same quarter in the previous year, the business earned ($3.83) EPS. On average, sell-side analysts anticipate that Arcadia Biosciences will post -2.29 earnings per share for the current year.
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Featured Articles
- Five stocks we like better than Arcadia Biosciences
- Profitably Trade Stocks at 52-Week Highs
- RXO Shares Surge Following New Acquisition Deal
- ESG Stocks, What Investors Should Know
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.